Mesenchymal Stem Cells with Specific Markers for Enhanced Barrier Function

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current mesenchymal stem cell therapies for various diseases, particularly those derived from umbilical cord tissue, exhibit limited therapeutic efficacy due to insufficient differentiation capacity and barrier function enhancement.

Innovation Solution

Development of mesenchymal stem cells expressing specific cell surface markers (CD201, CD46, CD56, CD147, and CD165) that secrete Crossveinless-2 and Ectodysplasin A2, along with cytokines like activin A, Dkk-3, and decorin, which are isolated and concentrated to create a pharmaceutical composition for enhanced therapeutic effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If mesenchymal stem cells are used for treating various diseases, then therapeutic effects are achieved, but the therapeutic efficacy is insufficient

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoiddifferentiation capacity

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent changes the phenotypic parameters of mesenchymal stem cells by inducing differentiation to specific lineages (osteogenic, chondrogenic, adipogenic, neurogenic) and selecting for cells expressing specific surface markers (CD201, CD46, CD56, CD147, CD165). This parameter change transforms the cells from a general multipotent state to a more specialized state with enhanced therapeutic efficacy for specific diseases.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent applies local quality by creating subpopulations of mesenchymal stem cells with specific differentiation capacities tailored to different tissue types. By isolating cells that can differentiate into specific lineages (bone, cartilage, fat, nerve) and by selecting for specific surface marker expressions, the patent creates locally optimized cell populations for specific therapeutic applications rather than using a uniform undifferentiated population.

Inventive Principle:

Principle #3Local quality

2Strength

If mesenchymal stem cells are used for tissue repair, then damaged tissues are repaired, but barrier function enhancement is insufficient

Engineering Contradiction:

Improvetissue repair capabilityVSAvoidbarrier function

Core Design Contradiction:

StrengthVSReliability

Solution Approach 1:

The patent applies preliminary action by pre-differentiating mesenchymal stem cells into specific lineages and pre-selecting for cells with enhanced barrier functions before administration. The cells are prepared in advance with specific phenotypic characteristics (surface marker expression, differentiation capacity) that will enable them to effectively restore barrier function in target tissues upon transplantation.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent changes cellular parameters by inducing differentiation and selecting for cells that express specific surface markers associated with barrier function. This transforms the cells from a general repair capability to a specialized function that specifically addresses barrier restoration in epithelial and endothelial tissues.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If mesenchymal stem cells are administered to treat diseases, then anti-inflammatory effects are achieved, but selectivity for specific diseases is limited

Engineering Contradiction:

Improveanti-inflammatory effectVSAvoiddisease specificity

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies local quality by creating specialized subpopulations of mesenchymal stem cells with specific surface marker profiles and differentiation capacities tailored to different disease types. By selecting for cells expressing specific combinations of surface markers (CD201, CD46, CD56, CD147, CD165) and differentiation potential, the patent creates locally optimized cell populations that can selectively target specific inflammatory conditions and tissue types.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent segments the general mesenchymal stem cell population into distinct subpopulations based on surface marker expression and differentiation capacity. This segmentation creates specialized cell types optimized for specific therapeutic applications, allowing selective administration for different disease categories (inflammatory diseases, cardiovascular diseases, metabolic disorders, cancer) rather than using a single undifferentiated population for all conditions.

Inventive Principle:

Principle #1Segmentation

Data Source

PatentUS11179420B2Method for treating a disease, comprising administering mesenchymal stem cells or culture supernatant thereof to a subject

Publication Date: 2021.11.23 ROHTO PHARM CO LTD

AI summary

An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects for various diseases, a novel pharmaceutical composition containing the mesenchymal stem cells, and methods for preparing these. The present invention provides mesenchymal stem cells expressing at least one cell surface marker selected from the group consisting of CD201, CD46, CD56, CD147 and CD165. The mesenchymal stem cells expressing such a specific marker are positive for CD29, CD73, CD90, CD105 and CD166, and maintain an undifferentiated state.